Vaccination coverage and immunity against hepatitis B among HIV-infected patients in South Brazil

Martins, Saulo; Livramento, Andréa do; Andrigueti, Michelle; Kretzer, Iara Fabrícia; Machado, Marcos José; Spada, Celso; Treitinger, Arício

doi:10.1016/j.bjid.2014.12.002

Cited by 21 publications

(35 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of these, 58.2% (78/134) had anti-HBs (data not shown). These findings were consistent with other studies in Brazil, which also reported a low HBV vaccination coverage rate [Pereira et al, 2006;Freitas et al, 2014;Martins et al, 2015]. Notably, 56.6% of the study participants are still susceptible to HBV infection.…”

Section: Discussionsupporting

confidence: 92%

Overt and occult hepatitis B virus infection among treatment‐naïve HIV‐infected patients in Brazil

Oliveira

Lemes

Matos

et al. 2016

Journal of Medical Virology

View full text Add to dashboard Cite

Although hepatitis B virus (HBV) and human immunodeficiency virus (HIV) co-infection is common, only few data are available on HBV among HIV patients including occult hepatitis B infection (OBI), regardless of serological markers. This study aims to determine the prevalence of OBI and overall HBV infection, associated factors, HBV genotypes, and surface (S) gene mutations in a population of treatment-naïve HIV-infected patients in Brazil. A cross-sectional study was conducted in treatment-naïve HIV-infected patients in Central Brazil. All samples were tested for HBV serological markers and HBV DNA. Sequence analysis of the S gene and overlapping polymerase gene was preformed. Overall, 25.1% (127/505) of the patients had markers of current or previous HBV infection, which was associated with age over 40 years, history of injection drug use, and homosexual sex. The hepatitis B surface antigen (HBsAg) seroprevalence was 4.9% (25/505). HBV DNA was detected in 39 out of 505 patients: 20 of them were HBsAg-positive and 19 were HBsAg-negative, resulting in an OBI prevalence of 3.8%. Patients with OBI had significantly higher HCV seropositivity rate compared to HBsAg-positive patients. Sequencing of the S gene revealed Y100C, T131N, and D144A mutations. One patient had the M204I and L180M drug-resistance mutations (polymerase). HBV genotypes A (A1, A2), D (D2, D3), and F (F2) were identified. In conclusion, OBI represented almost half of all HBV infections with detectable HBV DNA, suggesting that hepatitis B diagnosis in HIV patients should include in addition to serological markers the detection of HBV DNA.

show abstract

Section: Discussionsupporting

confidence: 92%

Overt and occult hepatitis B virus infection among treatment‐naïve HIV‐infected patients in Brazil

Oliveira

Lemes

Matos

et al. 2016

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…8,9 Despite these recommendations, in 2015, only 2 third of persons living with HIV receive at least one dose of HBV vaccine 20 y after the beginning of the HAART era. 101,102 Response rate is usually defined by a seroconversion with anti-HBs antibodies > 10UI/mL. In addition, response rates to the "classic" schedule (20 mg of HBs antigen at months 0-1-6) vaccination against HBV are lower in people living with HIV, since only 20 to 70% of HIVinfected adults were seroprotected vs 90 to 95% in non HIV infected people [11][12][13][14] The aim of this review is to summarize the currently available data regarding HBV vaccination in people living with HIV, according to their main characteristics and their vaccine and therapeutic background.…”

Section: Introductionmentioning

confidence: 99%

Hepatitis B virus vaccination in HIV-infected people: A review

Catherine

Piroth

2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

HBV immunization is highly recommended in people infected with HIV. However, the classical schedule used in the general population has been shown to be insufficient in people living with HIV. This review summarizes the main studies dealing with HBV vaccination in people living with HIV, depending on their baseline status (in particular, never vaccinated, already vaccinated, or with an isolated anti-HBc serological profile). It shows that reinforced 40µg intramuscular HBV vaccination schedules are now frequently recommended, either initially in people never vaccinated, or in the lack of an anamnestic response in other situations. Adjuvants cannot be currently recommended. Anti-HBs titers have to be checked 1 to 2 months following the last vaccine dose, and annually thereafter a booster is necessary if antiHBs titers decrease below 10 mIU/mL. In patients with a CD4 cell count <200/µL, guidelines recommend starting the vaccination regimen as soon as possible after HAART has been started.

show abstract

“…Regarding vaccination among other high-risk groups, 57% vaccination coverage among HIV-infected patients was assessed in South Brazil during 2012–13 [24]. Serological profiles among crack cocaine users in Central Brazil suggested a lower HB vaccination coverage (18%) [25].…”

Section: Resultsmentioning

confidence: 99%

Progress in vaccination towards hepatitis B control and elimination in the Region of the Americas

et al. 2017

View full text Add to dashboard Cite

BackgroundOver recent decades, the Region of the Americas has made significant progress towards hepatitis B elimination. We summarize the countries/territories’ efforts in introducing and implementing hepatitis B (HB) vaccination and in evaluating its impact on HB virus seroprevalence.MethodsWe collected information about HB vaccination schedules, coverage estimates, and year of vaccine introduction from countries/territories reporting to the Pan American Health Organization/World Health Organization (PAHO/WHO) through the WHO/UNICEF Joint Reporting Form on Immunization. We obtained additional information regarding countries/territories vaccination recommendations and strategies through communications with Expanded Program on Immunization (EPI) managers and national immunization survey reports. We identified vaccine impact studies conducted and published in the Americas.ResultsAs of October 2016, all 51 countries/territories have included infant HB vaccination in their official immunization schedule. Twenty countries, whose populations represent over 90% of the Region’s births, have included nationwide newborn HB vaccination. We estimated at 89% and 75%, the regional three-dose series and the birth dose HB vaccination coverage, respectively, for 2015. The impact evaluations of infant HB immunization programs in the Region have shown substantial reductions in HB surface antigen (HBsAg) seroprevalence.ConclusionThe achievements of vaccination programs in the Americas suggest that the elimination of perinatal and early childhood HB transmission could be feasible in the short-term. Moreover, the data gathered indicate that the Region may have already achieved the 2020 WHO goal for HB control.

show abstract

Vaccination coverage and immunity against hepatitis B among HIV-infected patients in South Brazil

Cited by 21 publications

References 28 publications

Overt and occult hepatitis B virus infection among treatment‐naïve HIV‐infected patients in Brazil

Overt and occult hepatitis B virus infection among treatment‐naïve HIV‐infected patients in Brazil

Hepatitis B virus vaccination in HIV-infected people: A review

Progress in vaccination towards hepatitis B control and elimination in the Region of the Americas

Contact Info

Product

Resources

About